Cover Image
市場調查報告書

全球液態切片產品分析:設備、附隨物產品、套件、消耗品、試劑、手法、用途、客戶

Liquid Biopsy Global Product Analysis: Instrumentation, Ancillaries, Kits, Consumables, Reagents, Methods, Applications and Clients

出版商 Laboratory Markets Limited 商品編碼 517609
出版日期 內容資訊 英文 187 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球液態切片產品分析:設備、附隨物產品、套件、消耗品、試劑、手法、用途、客戶 Liquid Biopsy Global Product Analysis: Instrumentation, Ancillaries, Kits, Consumables, Reagents, Methods, Applications and Clients
出版日期: 2017年05月29日 內容資訊: 英文 187 Pages
簡介

本報告提供全球液態切片產品的市場調查,各地區/主要國家、組織類型的產品利用趨勢,供應商及產品簡介,利用手法、用途、終端用戶等分析,藥物R&D的使用趨勢,未來展望與市場機會等彙整資料。

摘要整理

第1章 簡介

第2章 利用分析:主要各地區、國家

  • 全球
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區
  • 討論

第3章 利用分析:各地區、國家

  • 北美
  • 歐洲
  • 南美
  • 亞洲
  • 中東
  • 大洋洲
  • 討論

第4章 利用分析:各組織類型

  • 醫院
  • 研究機關
  • 大學
  • 企業
  • 醫療中心
  • 其他
  • 討論

第5章 產品分析

  • 產品、企業
  • 產品、手法
  • 產品、用途
  • 產品、地區
  • 產品、主要國家
  • 產品、組織類型
  • 討論

第6章 CTC (循環腫瘤細胞)

  • 供應商
  • 產品
  • 手法
  • 用途
  • 地區
  • 主要國家
  • 組織類型
  • 討論

第7章 外吐小體

  • 供應商
  • 產品
  • 手法
  • 用途
  • 地區
  • 主要國家
  • 組織類型
  • 討論

第8章 cfDNA (無細胞DNA)

  • 供應商
  • 產品
  • 手法
  • 用途
  • 地區
  • 主要國家
  • 組織類型
  • 討論

第9章 ctDNA (血中循環腫瘤DNA)

  • 供應商
  • 產品
  • 手法
  • 用途
  • 地區
  • 主要國家
  • 組織類型
  • 討論

第10章 其他的產品

  • 供應商
  • 產品
  • 手法
  • 用途
  • 地區
  • 主要國家
  • 組織類型
  • 討論

第11章 抗體

  • 供應商
  • 產品
  • 手法
  • 用途
  • 地區
  • 主要國家
  • 組織類型
  • 討論

第12章 影像

  • 企業
  • 產品
  • 手法
  • 用途
  • 地區
  • 主要國家
  • 組織類型
  • 討論

第13章 藥物R&D和液態切片

  • 組織
  • 藥物R&D的液態切片
  • 液態切片:各臨床階段
  • 臨床開發的液態切片的成長
  • CTC和臨床階段
  • 外吐小體和臨床階段
  • ctDNA和臨床階段
  • cfDNA和臨床階段
  • 肺癌和液態切片
  • 乳癌和液態切片
  • 前列腺癌和液態切片
  • 大腸癌和液態切片
  • 討論

第14章 市場機會

  • CTC
  • 外吐小體
  • cfDNA
  • ctDNA
  • 抗體
  • 診斷
  • 影像
  • 其他

第11章 討論

附錄

目錄

Summary

This market study provides a detailed analysis of laboratory products being used in the liquid biopsy field. These areas include instrumentation, ancillary equipment and systems, kit-based products, assays, consumables, reagents and others. The products profiled relate to all liquid biopsy strategies including circulating tumour cells, exosomes, circulating cell-free DNA (cfDNA), circulating cell-free tumour DNA (ctDNA) and other circulating genetic markers being explored in this field. These products are classified by company suppliers, product names, methods areas and by their applications in the liquid biopsy field. Overall, the study identified 128 company suppliers, 449 individual products by name, 195 method areas and 186 applications relating to liquid biopsy.

The report provides a competitive analysis across all of these product areas in the liquid biopsy field, covering global regions, countries and organisations types (e.g. hospitals, companies and institutes etc) as well as the names of the organisations profiled in this study. In carrying out this market analysis, we profiled over 700 methodology approaches and the associated products used, across all areas of the liquid biopsy field. We also used these findings to develop an extensive study file of more than 1500 organisations globally, where liquid biopsy is used. Our findings also enabled us to determine future liquid biopsy users in the years ahead and these findings (i.e. organisation names, countries etc) are also provided with the report as a source of qualified market leads to report purchasers.

Companies Mentioned

Liquid Biopsy Global Product Analysis covered products supplied by 128 companies that supply laboratory products used in the liquid biopsy field. These products included all cited consumables and reagents (e.g. chemicals, antibodies etc.,), all-in-one isolation kits (e.g. CTC, cfDNA, ctDNA, assays etc) and equipment or instrumentation (e.g. used in CTC, exosome or cell-free nucleic acid analysis, isolation, sample preparation, imaging etc.). These companies related to 449 individual products by name in 195 method areas and 186 applications relating to liquid biopsy. Example companies include Abbott Molecular, AdnaGen, Applied Biosystems, Axygen, BD Biosciences, Beckman Coulter, Becton Dickinson, ClearBridge Biomedics, Janssen, Macherey-Nagel, Systems Biosciences and Thermo Fisher Scientific.

Purpose of Market Study

This market study was carried out to identify new opportunities to suppliers in the liquid biopsy field. Its findings enable supplier to extend the reach of their existing products, as well as identify new market needs. The second, and we believe the most important goal of this study, is to enable suppliers to predict where the greatest developments and opportunities will be found in the liquid biopsy field in the coming years.

‘Liquid Biopsy Global Product Analysis' was carried out in two phases. The first phase involved a detailed analysis of current and evolving liquid-biopsy liquid biopsy current practices from reagent level upwards. The second phase used this information to identify where the greatest developments in the liquid biopsy field will take place over the next few years. The study file compiled during this study is also supplied to purchasers, alongside the PDF market report.

Market Areas

Global Regions

This market study was carried out in two phases, 1 and 2. Phase 1 of this study (see Purpose of Study) covered 7 regions, namely Asia, Europe, Middle East, North America, Northern Africa, Oceania, South America and Southern Africa and the data are also analysed across major regions too, namely the Americas, EMEA and Asia Pacific. This analysis was based on over 700 liquid biopsy methodology approaches cited by end-users (covering 128 laboratory suppliers, 449 individual products by name, 195 method areas and 186 applications relating to liquid biopsy. In Phase 2 of this study (see Purpose of Study), we used the information obtained on phase 1 in which we used the information obtained in Phase 1 to identify leading market areas and where the greatest market opportunities liquid biopsy field are anticipated to be found over the next few years. We covered the same regions and major regions, while in this case more than 1500 end-user organisations were identified. The compiled study files relating to liquid biopsy end-users in both phases of this study are provided to purchasers alongside the PDF market report.

Countries

Phase 1 of this study (see Purpose of Study) covered 37 countries including United States, China, Japan, Germany, Australia, UK, Spain, South Korea, Italy, Sweden, Canada, France, Greece and Poland. In Phase 2 of this study our analysis covered more than 40 countries, which included all 'top market ranking' countries identified in Phase 1 of our study.

Organisation Types

Phase 1 of this study (see Purpose of Study) covered 18 organisation types including hospitals, institutes, universities, companies, medical centres and others. In Phase 2 of this study our analysis covered more than 25 organisation types, which included all 'top market ranking' organisation types identified in Phase 1 of our study.

Circulating Tumour Cells

In Phase 1 of this study (see Purpose of Study) our analysis covered all identified methods and practices relating to the isolation, enrichment, identification, analysis and the study of CTCs in the context of liquid biopsies. In Phase 2 of this study our analysis covered all organisations working with CTCs, as well as other 'top ranking' market areas, identified in Phase 1 of our study.

Exosomes

In Phase 1 of this study (see Purpose of Study) our analysis covered all identified methods and practices relating to the isolation, enrichment, identification, analysis and study of exosomes in the context of liquid biopsies. In Phase 2 of this study our analysis covered all organisations working with exosomes, as well as other 'top ranking' market areas, identified in Phase 1 of our study.

Circulating Cell-Free Nucleic Acids

In Phase 1 of this study (see Purpose of Study) our analysis covered all identified methods and practices relating to the isolation, enrichment, identification, analysis and study of circulating cell-free nucleic acids (cfDNA, cfRNA, ctDNA and others) in the context of liquid biopsies. In Phase 2 of this study our analysis covered all organisations working with circulating cell-free nucleic acids (cfDNA, cfRNA, ctDNA and others), as well as other 'top ranking' market areas, identified in Phase 1 of our study.

Laboratory Suppliers

Our study identified and profiled (by product, method area, applications and other areas) 128 companies that supply products relating to liquid biopsies. These companies cover all of the product areas evaluated in this study including instrumentation, ancillary equipment and systems, kit-based products, assays, reagents and consumables.

Products

This market study provides a detailed analysis of laboratory products (449 identified) that are area being used in the liquid biopsy field. These product areas include instrumentation, ancillary equipment and ancillary systems, kit-based products in all areas and consumables from reagent levels upwards.

Method Areas

This market study carried out a detailed analysis of the method areas relating to the liquid biopsy products profiled in this study. This market analysis identified 195 methodology areas, which were also segmented by application and other sectors covered in this study.

Applications

This market study carried out a detailed analysis of the application areas relating to the liquid biopsy method areas profiled in this study. This market analysis identified 186 applications, which were also segmented by methods and other sectors covered in this study.

Drug R&D

As part of the market analysis carried out in this study, we also analysed the use of liquid biopsy interventions in clinical trials, where these techniques are incorporated as part of the clinical protocols. This identified 448 clinical trials, of which 179 are being progressed by (primarily pharmaceutical and diagnostic) companies. This part of the study included all of the current liquid biopsy methodologies identified earlier in this study (CTCs, exosomes circulating cell-free nucleic acids) and covered clinical trial phase and start dates, which has allowed the growth (numbers of trials) in this sector to be calculated.

Diagnostics

Diagnostics is at the heart of the liquid biopsy field and this study identified diagnostics companies both as suppliers into laboratories and involved in the conduct of clinical trials in this field. These companies have also been segmented across all other areas of the study, notably relating to CTCs, exosomes, circulating cells-free nucleic acids, methods and applications.

Antibodies

Antibodies are very vitally important in the liquid biopsy field, for many different reasons. As part of this study antibodies have been covered in some depth, with 53 different antibodies (21 companies) and 22 conjugated antibodies (10 companies) identified. This antibodies and conjugated antibodies have also been segmented across all other areas of the study, notably relating to CTCs, exosomes, circulating cells-free nucleic acids, methods and applications.

Imaging

Imaging is also important in the liquid biopsy field and as part of this study imaging has been covered this in some depth, where we identified 26 companies and 46 products, systems or platforms or ancillaries. Imaging methods have also been segmented across all other areas of the study, notably relating to CTCs, exosomes, circulating cells-free nucleic acids, methods and applications.

Market Opportunities

The identification of market opportunities was a key goal in the conduct of this market study. Findings relating to opportunities were made through the detailed stratification of products, methods and applications relating to CTCs, exosomes and circulating nucleic acids, which identified where and how these products are being used. Phase 2 of this study also identified more than 1500 end-user organisations in the liquid biopsy field, providing a valuable source of market prospects to suppliers.

Future Use

The future anticipated use liquid biopsy methodologies was analysed in Phase 2 of this study, which used the findings compiled in Phase I to identify the top users globally. This covered the major sectors of the liquid biopsy field, including CTCs, exosomes and circulating cell-free nucleic acids. This part of the study also allowed us to calculate the growth of these activities from market develops seen in the liquid biopsy field between 2014 and 2017.

Market Growth

The future anticipated use liquid biopsy methodologies was also analysed in Phase 2 of this study, which used the findings compiled in Phase I to identify the top users globally. This covered the major sectors of the liquid biopsy field, including CTCs, exosomes and circulating cell-free nucleic acids.

Clients

As part of Phase 1 and Phase 2 of this study, we identified liquid biopsy end-users by organisation name. These are segmented globally and by country and across all other areas of the study, enabling specific activities in this field to be directly linked to the organisations themselves. The compiled data files of phases 1 and 2 of this study are provided to purchasers alongside the PDF market report.

Table of Contents

Report Index

Discussion areas in this market report include:

  • Opportunities
  • Leading and growing market areas
  • Leading liquid biopsy laboratory products in all categories
  • Top suppliers
  • Market drivers
  • Product limitations
  • Leading methods and applications
  • Top global, regional and country-wide markets
  • Anticipated future developments
  • Growth
  • Emerging areas

EXECUTIVE SUMMARY

1. INTRODUCTION

2. MAJOR REGIONS AND COUNTRIES

  • 2.1. Global Liquid Biopsy
    • Figure 1. Liquid biopsy use globally (Study Number LBIO17)
    • Table 1. Liquid biopsy use globally (Study Number LBIO17)
  • 2.2. Americas
    • Figure 2. Liquid biopsy use across the Americas (Study Number LBIO17)
    • Table 2. Liquid biopsy use across the Americas (Study Number LBIO17)
  • 2.3. EMEA Liquid Biopsy
    • Figure 3. Liquid biopsy use across EMEA (Study Number LBIO17)
    • Table 3. Liquid biopsy use across EMEA (Study Number LBIO17)
  • 2.4. Asia Pacific Liquid Biopsy
    • Figure 4. Liquid biopsy use across Asia Pacific (Study Number LBIO17)
    • Table 4. Liquid biopsy use across Asia Pacific (Study Number LBIO17)
  • 2.5. Discussion

3. REGIONS AND COUNTRIES

  • 3.1. North America Liquid Biopsy
    • Figure 5. Liquid biopsy use in North America (Study Number LBIO17)
    • Table 5. Liquid biopsy use in North America (Study Number LBIO17)
  • 3.2. Europe Liquid Biopsy
    • Figure 6. Liquid biopsy use in Europe (Study Number LBIO17)
    • Table 6. Liquid biopsy use in Europe (Study Number LBIO17)
  • 3.3. South America Liquid Biopsy
    • Figure 7. Liquid biopsy use in South America (Study Number LBIO17)
    • Table 7. Liquid biopsy use in South America (Study Number LBIO17)
  • 3.4. Asia Liquid Biopsy
    • Figure 8. Liquid biopsy use in Asia (Study Number LBIO17)
    • Table 8. Liquid biopsy use in Asia (Study Number LBIO17)
  • 3.5. Middle East Liquid Biopsy
    • Figure 9. Liquid biopsy use in the Middle East (Study Number LBIO17)
    • Table 9. Liquid biopsy use in the Middle East (Study Number LBIO17)
  • 3.6. Oceania Liquid Biopsy
    • Figure 10. Liquid biopsy use in Oceania (Study Number LBIO17)
    • Table 10. Liquid biopsy use in Oceania (Study Number LBIO17)
  • 3.7. Discussion

4. ORGANISATION TYPES

  • 4.1. Global
    • Figure 11. Liquid biopsy use by organisation type Globally (Study Number LBIO17)
    • Table 11. Liquid biopsy use by organisation type Globally (Study Number LBIO17)
  • 4.2. North America Liquid Biopsy
    • Figure 12. Liquid biopsy use by organisation type in North America (Study Number LBIO17)
    • Table 12. Liquid biopsy use by organisation type in North America (Study Number LBIO17)
  • 4.3. Europe Liquid Biopsy
    • Figure 13. Liquid biopsy use by organisation type in Europe (Study Number LBIO17)
    • Table 13. Liquid biopsy use by organisation type in Europe (Study Number LBIO17)
  • 4.4. South America Liquid Biopsy
    • Figure 14. Liquid biopsy use by organisation type In South America (Study Number LBIO17)
    • Table 14. Liquid biopsy use by organisation type in South America (Study Number LBIO17)
  • 4.5. Asia Liquid Biopsy
    • Figure 15. Liquid biopsy use by organisation type in Asia (Study Number LBIO17)
    • Table 15. Liquid biopsy use by organisation type in Asia (Study Number LBIO17)
  • 4.6. Middle East Liquid Biopsy
    • Figure 16. Liquid biopsy use by organisation type in the Middle East (Study Number LBIO17)
    • Table 16. Liquid biopsy use by organisation type in the Middle East (Study Number LBIO17)
  • 4.7. Oceania Liquid Biopsy
    • Figure 17. Liquid biopsy use by organisation type in Oceania (Study Number LBIO17)
    • Table 17. Liquid biopsy use by organisation type in Oceania (Study Number LBIO17)
  • 4.8. Discussion

5. LIQUID BIOPSY PRODUCTS

  • 5.1. Products and Companies
    • Figure 18. Liquid biopsy products and companies (Study Number LBIO17)
    • Table 18. Liquid biopsy products and companies (Study Number LBIO17)
  • 5.2. Products and Methods
    • Figure 19. Liquid biopsy products and methods (Study Number LBIO17)
    • Table 19. Liquid biopsy products and methods (Study Number LBIO17)
  • 5.3. Products and Applications
    • Figure 20. Liquid biopsy products and applications (Study Number LBIO17)
    • Table 20. Liquid biopsy products and applications (Study Number LBIO17)
  • 5.4. Products and Regions
    • Figure 21. Liquid biopsy products and regions (Study Number LBIO17)
    • Table 21. Liquid biopsy products and regions (Study Number LBIO17)
  • 5.5. Products and Countries
    • Figure 22. Liquid biopsy products and countries (Study Number LBIO17)
    • Table 22. Liquid biopsy products and countries (Study Number LBIO17)
  • 5.6. Products and Organisation Types
    • Figure 23. Liquid biopsy products and organisation types (Study Number LBIO17)
    • Table 23. Liquid biopsy products and organisation types (Study Number LBIO17)
  • 5.7. Discussion

6. CIRCULATING TUMOUR CELLS

  • 6.1. CTC Companies
    • Figure 24. CTCs and company suppliers (Study Number LBIO17)
    • Table 24. CTCs and company suppliers (Study Number LBIO17)
  • 6.2. CTC Products
    • Figure 25. CTCs and products (Study Number LBIO17)
    • Table 25. CTCs and products (Study Number LBIO17)
  • 6.3. CTC Methods
    • Figure 26. CTCs and methods (Study Number LBIO17)
    • Table 26. CTCs and methods (Study Number LBIO17)
  • 6.4. CTC Applications
    • Figure 27. CTCs and applications (Study Number LBIO17)
    • Table 27. CTCs and applications (Study Number LBIO17)
  • 6.5. CTC Regions
    • Figure 28. CTCs and Regions (Study Number LBIO17)
    • Table 28. CTCs and regions (Study Number LBIO17)
  • 6.6. CTC Countries
    • Figure 29. CTCs and top countries (Study Number LBIO17)
    • Table 29. CTCs and top countries (Study Number LBIO17)
  • 6.7. CTC Organisation Types
    • Figure 30. CTCs and organisation types (Study Number LBIO17)
    • Table 30. CTCs and organisation types (Study Number LBIO17)
  • 6.8. Discussion

7. EXOSOMES

  • 7.1. Exosome Companies
    • Figure 31. Exosomes and company suppliers (Study Number LBIO17)
    • Table 31. Exosomes and company suppliers (Study Number LBIO17)
  • 7.2. CTC Products
    • Figure 32. Exosomes and products (Study Number LBIO17)
    • Table 22. Exosomes and products (Study Number LBIO17
  • 7.3. Exosome Methods
    • Figure 33. Exosomes and methods (Study Number LBIO17)
    • Table 33. Exosomes and methods (Study Number LBIO17)
  • 7.4. Exosome Applications
    • Figure 34. Exosomes and applications (Study Number LBIO17)
    • Table 34. Exosomes and applications (Study Number LBIO17)
  • 7.5. Exosome Regions
    • Figure 35. Exosomes and regions (Study Number LBIO17)
    • Table 35. Exosomes and regions (Study Number LBIO17)
  • 7.6. Exosome Countries
    • Figure 36. Exosomes and top countries (Study Number LBIO17)
    • Table 36. Exosomes and top countries (Study Number LBIO17)
  • 7.7. Exosome Organisation Types
    • Figure 37. Exosomes and organisation types (Study Number LBIO17)
    • Table 37. Exosomes and organisation types (Study Number LBIO17)
  • 7.8. Discussion

8. CIRCULATING CELL-FREE DNA

  • 8.1. cfDNA Companies
    • Figure 38. cfDNA and company suppliers (Study Number LBIO17)
    • Table 38. cfDNA and company suppliers (Study Number LBIO17)
  • 8.2. CTC Products
    • Figure 39. cfDNA and products (Study Number LBIO17)
    • Table 39. cfDNA and products (Study Number LBIO17
  • 8.3. cfDNA Methods
    • Figure 40. cfDNA and methods (Study Number LBIO17)
    • Table 40. cfDNA and methods (Study Number LBIO17)
  • 8.4. cfDNA Applications
    • Figure 41. cfDNA and applications (Study Number LBIO17)
    • Table 41. cfDNA and applications (Study Number LBIO17)
  • 8.5. cfDNA Regions
    • Figure 42. cfDNA and Regions (Study Number LBIO17)
    • Table 42. cfDNA and regions (Study Number LBIO17)
  • 8.6. cfDNA Countries
    • Figure 43. cfDNA and top countries (Study Number LBIO17)
    • Table 43. cfDNA and top countries (Study Number LBIO17)
  • 8.7. cfDNA Organisation Types
    • Figure 44. cfDNA and organisation types (Study Number LBIO17)
    • Table 44. cfDNA and organisation types (Study Number LBIO17)
  • 8.8. Discussion

9. CIRCULATING CELL-FREE TUMOUR DNA

  • 9.1. ctDNA Companies
    • Figure 45. ctDNA and company suppliers (Study Number LBIO17)
    • Table 45. ctDNA use an company suppliers (Study Number LBIO17)
  • 9.2. CTC Products
    • Figure 46. ctDNA and products (Study Number LBIO17)
    • Table 46. ctDNA and products (Study Number LBIO17
  • 9.3. ctDNA Methods
    • Figure 47. ctDNA use and methods (Study Number LBIO17)
    • Table 47. ctDNA use and methods (Study Number LBIO17)
  • 9.4. ctDNA Applications
    • Figure 48. ctDNA use and applications (Study Number LBIO17)
    • Table 48. ctDNA use and applications (Study Number LBIO17)
  • 9.5. ctDNA Regions
    • Figure 49. ctDNA use and regions (Study Number LBIO17)
    • Table 49. ctDNA use and regions (Study Number LBIO17)
  • 9.6. ctDNA Countries
    • Figure 50. ctDNA use and top countries (Study Number LBIO17)
    • Table 50. ctDNA use and top countries (Study Number LBIO17)
  • 9.7. ctDNA Organisation Types
    • Figure 51. ctDNA use and organisation types (Study Number LBIO17)
    • Table 51. ctDNA use and organisation types (Study Number LBIO17)
  • 9.8. Discussion

10. OTHER PRODUCTS

  • 10.1. Other Companies
    • Figure 52. Other products and companies (Study Number LBIO17)
    • Table 52. Other products and companies (Study Number LBIO17)
  • 10.2. CTC Products
    • Figure 53. Other products (Study Number LBIO17)
    • Table 53. Other products (Study Number LBIO17
  • 10.3. Other Methods
    • Figure 54. Other products and methods (Study Number LBIO17)
    • Table 54. Other products and methods (Study Number LBIO17)
  • 10.4. Other Applications
    • Figure 55. Other products and applications (Study Number LBIO17)
    • Table 55. Other products and applications (Study Number LBIO17)
  • 10.5. Other Regions
    • Figure 56. Other products and regions (Study Number LBIO17)
    • Table 56. Other products and regions (Study Number LBIO17)
  • 10.6. Other Countries
    • Figure 57. Other products and top countries (Study Number LBIO17)
    • Table 57. Other products and top countries (Study Number LBIO17)
  • 10.7. Other Organisation Types
    • Figure 58. Other products and organisation types (Study Number LBIO17)
    • Table 58. Other products and organisation types (Study Number LBIO17)
  • 10.8. Discussion

11. ANTIBODIES

  • 11.1. Antibody Companies
    • Figure 59. Antibodies and companies (Study Number LBIO17)
    • Table 59. Antibodies and companies (Study Number LBIO17)
  • 11.2. CTC Products
    • Figure 60. Antibodies and products (Study Number LBIO17)
    • Table 60. Antibodies and products (Study Number LBIO17
  • 11.3. Antibody Methods
    • Figure 61. Antibodies and methods (Study Number LBIO17)
    • Table 61. Antibodies and methods (Study Number LBIO17)
  • 11.4. Antibody Applications
    • Figure 62. Antibodies and applications (Study Number LBIO17)
    • Table 62. Antibodies and applications (Study Number LBIO17)
  • 11.5. Antibody Regions
    • Figure 63. Antibodies and regions (Study Number LBIO17)
    • Table 63. Antibodies and regions (Study Number LBIO17)
  • 11.6. Antibody Countries
    • Figure 64. Antibodies and top countries (Study Number LBIO17)
    • Table 64. Antibodies and top countries (Study Number LBIO17)
  • 11.7. Antibody Organisation Types
    • Figure 65. Antibodies and organisation types (Study Number LBIO17)
    • Table 65. Antibodies and organisation types (Study Number LBIO17)
  • 11.8. Discussion

12. IMAGING

  • 12.1. Imaging Companies
    • Figure 66. Imaging and companies (Study Number LBIO17)
    • Table 66. Imaging and companies (Study Number LBIO17)
  • 12.2. Imaging Products
    • Figure 67. Imaging and products (Study Number LBIO17)
    • Table 67. Imaging and products (Study Number LBIO17
  • 12.3. Imaging Methods
    • Figure 68. Imaging and methods (Study Number LBIO17)
    • Table 68. Imaging and methods (Study Number LBIO17)
  • 12.4. Imaging Applications
    • Figure 69. Imaging and applications (Study Number LBIO17)
    • Table 69. Imaging and applications (Study Number LBIO17)
  • 12.5. Imaging Regions
    • Figure 70. Imaging and regions (Study Number LBIO17)
    • Table 70. Imaging and regions (Study Number LBIO17)
  • 12.6. Imaging Countries
    • Figure 71. Imaging and top countries (Study Number LBIO17)
    • Table 71. Imaging and top countries (Study Number LBIO17)
  • 12.7. Imaging Organisation Types
    • Figure 72. Imaging and organisation types (Study Number LBIO17)
    • Table 71. Imaging and organisation types (Study Number LBIO17)
  • 12.8. Discussion

13. DRUG R&D AND LIQUID BIOPSIES

  • 13.1. Organisations
    • Figure 73. Liquid biopsy and clinical organisations (Study Number LBIO17)
    • Table 73. Liquid biopsy and clinical organisations (Study Number LBIO17)
  • 13.2. Liquid Biopsy in Drug R&D
    • Figure 74. Liquid biopsy and drug R&D (Study Number LBIO17)
    • Table 74. Liquid biopsy and drug R&D (Study Number LBIO17)
  • 13.3. Liquid Biopsy by Clinical Phase
    • Figure 75. Liquid biopsy and clinical phase (Study Number LBIO17)
    • Table 75. Liquid biopsy and clinical phase (Study Number LBIO17)
  • 13.4. Growth of Liquid Biopsy in Clinical development
    • Figure 76. Growth in liquid biopsy in clinical R&D (Study Number LBIO17)
    • Table 76. Growth in liquid biopsy in clinical R&D (Study Number LBIO17)
  • 13.5. CTCs and Clinical Phase
    • Figure 77. CTCs and Clinical Phase (Study Number LBIO17)
    • Table 77. CTCs and Clinical Phase (Study Number LBIO17)
  • 13.6. Exosomes and Clinical Phase
    • Figure 78. Exosomes and Clinical Phase (Study Number LBIO17)
    • Table 78. Exosomes and Clinical Phase (Study Number LBIO17)
  • 13.7. ctDNA and Clinical Phase
    • Figure 79. ctDNA and Clinical Phase (Study Number LBIO17)
    • Table 79. ctDNA and Clinical Phase (Study Number LBIO17)
  • 13.8. cfDNA and Clinical Phase
    • Figure 80. cfDNA and Clinical Phase (Study Number LBIO17)
    • Table 80. cfDNA and Clinical Phase (Study Number LBIO17)
  • 13.9. Lung Cancer and Liquid Biopsy
    • Figure 81. Lung Cancer and Liquid Biopsy (Study Number LBIO17)
    • Table 81. Lung Cancer and Liquid Biopsy (Study Number LBIO17)
  • 13.10. Breast Cancer and Liquid Biopsy
    • Figure 82. Breast Cancer and Liquid Biopsy (Study Number LBIO17)
    • Table 82. Breast Cancer and Liquid Biopsy (Study Number LBIO17)
  • 13.11. Prostate Cancer and Liquid Biopsy
    • Figure 83. Prostate Cancer and Liquid Biopsy (Study Number LBIO17)
    • Table 83. Prostate Cancer and Liquid Biopsy (Study Number LBIO17)
  • 13.12. Colorectal Cancer and Liquid Biopsy
    • Figure 84. Colorectal Cancer and Liquid Biopsy (Study Number LBIO17)
    • Table 84. Colorectal Cancer and Liquid Biopsy (Study Number LBIO17)
  • 13.13. Discussion

14. OPPORTUNITIES

  • 14.1. CTCs
    • Figure 85. CTC opportunities (Study Number LBIO17)
    • Table 85. CTC opportunities (Study Number LBIO17)
  • 14.2. exosomes
    • Figure 86. Exosome opportunities (Study Number LBIO17)
    • Table 86. Exosome opportunities (Study Number LBIO17)
  • 14.3. cfDNA
    • Figure 87. cfDNA opportunities (Study Number LBIO17)
    • Table 87. cfDNA opportunities (Study Number LBIO17)
  • 14.4. ctDNA
    • Figure 88. ctDNA opportunities (Study Number LBIO17)
    • Table 88. ctDNA opportunities (Study Number LBIO17)
  • 14.5. Antibodies
    • Figure 89. Antibody opportunities (Study Number LBIO17)
    • Table 89. Antibody opportunities (Study Number LBIO17)
  • 14.6. Diagnostics
    • Figure 90. Diagnostics opportunities (Study Number LBIO17)
    • Table 90. Diagnostics opportunities (Study Number LBIO17)
  • 14.7. Imaging
    • Figure 91. Imaging opportunities globally (Study Number LBIO17)
    • Table 81. Imaging opportunities (Study Number LBIO17)
  • 14.8. Others
    • Figure 92. Other opportunities (Study Number LBIO17)
    • Table 81. Other opportunities (Study Number LBIO17)

15. DISCUSSION

APPENDIX 1

  • Global Products in Liquid Biopsy
Back to Top